MCK Mckesson Dashboard

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, its employees work every day to innovate and deliver opportunities that make our customers and partners more successful - all for the better health of patients. McKesson has been named a 'Most Admired Company' in the healthcare wholesaler category by FORTUNE, a 'Best Place to Work' by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly.

Company profile

Ticker

MCK

Exchange

NYSE

Website

www.mckesson.com

CEO

Brian Tyler

Incorporated

Delaware

Location

Texas

Fiscal year end

Mar 31

Sector

Wholesale Trade > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Wholesale - Drugs, Proprietaries & Druggists' Sundries

Cardinal Health • Amerisource Bergen • Herbalife Nutrition • Nu Skin Enterprises • PetIQ • Merion • Trxade Health • Cosmos • Can B • Mu Yan Technology ...

Former names

MCKESSON HBOC INC

SEC CIK

0000927653

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943207296

MCK stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Stocks That Hit 52-Week Highs On Friday

30 Jul 21

On Friday morning, 154 companies achieved new highs for the year.

Stocks That Hit 52-Week Highs On Thursday

29 Jul 21

Thursday's morning session saw 167 companies set new 52-week highs.

Stocks That Hit 52-Week Highs On Monday

26 Jul 21

This morning 121 companies reached new 52-week highs.

Drug Distributors To Pay Up To $1.1B To Settle New York Opioid Claims

20 Jul 21

Joint Statement From AmerisourceBergen, Cardinal Health And McKesson Says Companies Agreed T Pay Up To $1.179B In Settlement With State Of New York To Resolve Opioid-Related Claims

20 Jul 21

Press releases

Pro users get this 30m faster

McKesson Raises Quarterly Dividend by 12% to $0.47 Per Share

26 Jul 21

The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of $0.47 per share of common stock, a 12% increase from $0.42 per share in the prior quarter. The dividend will be

McKesson Corporation Announces Pricing and Upsizing of Tender Offer

22 Jul 21

McKesson Corporation (NYSE:MCK) (the "Company") today announced the determination of the Full Tender Offer Consideration, as shown in the table below, for its previously announced cash tender offer to purchase up to

Distributors Announce Proposed Opioid Settlement Agreement

21 Jul 21

AmerisourceBergen (NYSE:ABC), Cardinal Health (NYSE:CAH) and McKesson (NYSE:MCK) announced today that they have negotiated a comprehensive proposed settlement agreement which, if all conditions are satisfied, would

Thinking about trading options or stock in McKesson Corp, Cardinal Health, TAL Education Group, Cassava Sciences, or Moderna?

20 Jul 21

Distributors Reach Opioid Settlement Agreement With New York State

20 Jul 21

Calendar

12 May 21

2 Aug 21

31 Mar 22

Financial summary

Financial statements Chart MCK financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 21	Mar 20	Mar 19	Mar 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Mckesson earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.4B	6.4B	6.4B	6.4B	6.4B	6.4B
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	(positive/no burn)	416.75M	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	n/a	1.71B	n/a	n/a
Cash remaining	n/a	n/a	n/a	4.69B	n/a	n/a
Runway (months of cash)	n/a	n/a	n/a	11.3	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

MCK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Jul 21	Mueller Edward A	RSU Common Stock	Grant	Aquire A	No	No	0	593	0	593
23 Jul 21	Mueller Edward A	RSU Common Stock	Grant	Aquire A	No	No	0	889	0	889
23 Jul 21	Knowles Marie L	Common Stock	Grant	Aquire A	No	No	202.63	7,551	1.53M	7,551
23 Jul 21	Knowles Marie L	RSU Common Stock	Sale back to company	Dispose D	No	No	0	2,551	0	0
23 Jul 21	Knowles Marie L	RSU Common Stock	Sale back to company	Dispose D	No	No	0	2,500	0	0
23 Jul 21	Knowles Marie L	RSU Common Stock	Sale back to company	Dispose D	No	No	0	2,500	0	0
23 Jul 21	Salka Susan R	RSU Common Stock	Grant	Aquire A	No	No	0	889	0	889
23 Jul 21	Washington Kenneth E	RSU Common Stock	Grant	Aquire A	No	No	0	889	0	889
23 Jul 21	Martinez Maria	RSU Common Stock	Grant	Aquire A	No	No	0	889	0	889

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

MCK institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

85.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	927	929	-0.2%
Opened positions	98	162	-39.5%
Closed positions	100	81	+23.5%
Increased positions	329	301	+9.3%
Reduced positions	328	316	+3.8%

13F shares	Current	Prev Q	Change
Total value	26.42B	23.89B	+10.6%
Total shares	135.63M	137.38M	-1.3%
Total puts	873.6K	1.54M	-43.1%
Total calls	1.06M	1.24M	-14.6%
Total put/call ratio	0.8	1.2	-33.4%

Largest owners	Shares	Value	Change
Vanguard	15.94M	$3.11B	-1.9%
BLK Blackrock	14.38M	$2.8B	+2.9%
JPM JPMorgan Chase & Co.	7.64M	$1.49B	+6.0%
STT State Street	6.95M	$1.36B	-5.5%
Massachusetts Financial Services	5.85M	$1.14B	-1.0%
FMR	3.84M	$748.13M	+6.7%
IVZ Invesco	3.78M	$737.07M	+7.9%
PZN Pzena Investment Management	3.05M	$594.99M	-1.3%
Geode Capital Management	2.88M	$559.95M	+2.3%
Boston Partners	2.86M	$556.91M	+0.6%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	0	-1.83M	EXIT
Ci Investments	543.71K	-731.41K	-57.4%
AMP Ameriprise Financial	1.03M	+653.44K	+173.1%
Swedbank	0	-600.06K	EXIT
Glenview Capital Management	1.76M	+593.02K	+50.8%
Los Angeles Capital Management & Equity Research	649.37K	+554.12K	+581.8%
Caisse De Depot Et Placement Du Quebec	432.88K	-552.16K	-56.1%
JPM JPMorgan Chase & Co.	7.64M	+434.16K	+6.0%
Ceredex Value Advisors	0	-415.2K	EXIT
BLK Blackrock	14.38M	+409.38K	+2.9%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Cardinal Health • VASO • Actavis • Omnicell • Exelixis • Henry Schein • Impax Laboratories • Medical Information Technology • Amerisource Bergen • Jazz Pharmaceuticals

Risks

We experience costly and disruptive legal disputes.
We might experience losses not covered by insurance.
We experience costly legal disputes, government actions and adverse publicity regarding our role in distributing controlled substances such as opioids.
We might experience increased costs to distribute controlled substances such as opioids.
We are subject to extensive, complex and challenging healthcare and other laws.
We are subject to extensive and frequently changing local, state and federal laws and regulations relating to healthcare fraud, waste and abuse.
We might lose our ability to purchase, compound, store or distribute pharmaceuticals and controlled substances.
Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs.
Privacy and data protection laws increase our compliance burden.
Anti-bribery and anti-corruption laws increase our compliance burden.
We might record significant charges from impairment to goodwill, intangibles and other assets or investments.
We experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches.
We might experience significant problems with information systems or networks.
Our products or services might not conform to specifications or perform as we intend.
We might be impeded in providing customers online services and data access.
We might not realize expected benefits from business process initiatives.
We might be unable to successfully complete or integrate acquisitions or other business combinations.
Exclusive forum provisions in our Bylaws could limit our stockholders’ ability to choose their preferred judicial forum for disputes with us or our directors, officers or employees.
We might be adversely impacted by delays or other difficulties with divestitures.
We might not realize the expected tax treatment from our split-off of Change Healthcare.
We might be adversely impacted by outsourcing or similar third-party relationships.
We may be unsuccessful in retail pharmacy operations or maintaining profitability.
We might be harmed by large customer purchase reductions, payment defaults or contract non-renewal.
Our contracts with government entities involve future funding and compliance risks.
Our participation in vaccination distribution programs may materially affect our operating results, reputation, and business.
We might be harmed by changes in our relationships or contracts with suppliers.
We might infringe intellectual property rights or our intellectual property protections might be inadequate.
We might be unable to successfully recruit and retain qualified employees.
We might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
We might be adversely impacted by competition and industry consolidation.
We might be adversely impacted by changes or disruptions in product supply.
We might be adversely impacted as a result of our distribution of generic pharmaceuticals.
We might be adversely impacted by an economic slowdown or recession.
Disruption or other changes in capital and credit markets might impede access to credit and increase borrowing costs for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers.
We may have difficulties in sourcing or selling products due to a variety of causes.
We might be adversely impacted by tax legislation or challenges to our tax positions.
We might be adversely impacted by the Brexit withdrawal of the United Kingdom from the European Union.
We might be adversely impacted by fluctuations in foreign currency exchange rates.
We might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events.
We may be adversely affected by global climate change or by legal, regulatory or market responses to such change.
We might be adversely impacted by changes in accounting standards.

Management Discussion

U.S. Pharmaceutical revenues for the year ended March 31, 2021 increased 4% compared to the prior year primarily due to market growth, including branded pharmaceutical price increases, growth in specialty pharmaceuticals, and higher volumes from retail national account customers, partially offset by branded to generic drug conversions. Revenues for this segment were unfavorably impacted by fluctuations in demand for pharmaceuticals in retail pharmacies and institutional healthcare providers due to COVID-19 largely during the onset of the pandemic in late March 2020 and during our first quarter of 2021 combined with the loss of certain customers.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: absent, accessible, ace, African, AIG, AIU, Alaska, alcohol, appellate, area, ASC, Asian, ASU, banc, Belgian, belonging, biopharma, Black, built, ca, Cal, candid, captive, career, choose, cleaning, clear, climate, clothing, coaching, Codification, cold, color, composition, concert, constitutionality, cough, culture, dba, debate, decommissioning, deep, DEI, demographic, demurred, destruction, diluent, disaggregated, discourage, disinfect, disinfecting, disparate, distinguish, donate, donation, easily, EBITDA, eCommerce, embrace, embracing, en, encourage, energy, entertainment, ESG, EUA, EURIBOR, Excellence, expedited, expertise, facial, feedback, feel, fell, flu, fluid, foot, forum, gas, gear, GHG, greenhouse, Guardian, guiding, hardest, Hart, Hawaiian, healthier, healthy, Hispanic, hit, IDA, ILEAD, ill, inapplicable, infected, infection, inflow, inquiry, Inspire, INVIVA, Janssen, kit, kitting, Latino, leadership, Leasehold, led, lesser, Leverage, lifecycle, Logix, machinery, MacroHelix, mandate, mental, mindset, mission, Moderna, ModernaTX, mortality, mount, MPA, multistate, Native, NDCHealth, NV, onset, Ontada, overturned, Pa, paused, peaking, philanthropy, Pittsburgh, platform, playing, population, precluded, prep, presence, prioritization, procedural, Proxim, PTO, question, rationalization, rationalize, ready, reallocated, reallocation, recast, refrigerated, reinstated, rejected, rejecting, repurpose, SA, sea, seamlessly, segregation, sense, Shoppe, situation, space, spoilage, storm, strive, Subtopic, superseded, survey, telehealth, temperature, temporarily, therapy, thereto, thrive, Tom, Topic, transformational, umbrella, unaffected, unenforceable, unfinalized, unified, unprecedented, unprofitable, VII, VIII, viral, visibility, vision, voluntary, wash, WBA, weather, window, winter, women, workplace

Removed: acquirer, age, aging, assigned, attained, BDI, biotechnology, book, call, callable, combine, complexity, computer, concentrated, continuously, corroborated, creditable, Cuyahoga, cyber, diversification, doubt, earliest, EIS, eliminating, equitable, exclude, extinguished, France, freeze, generate, hereof, highest, history, imposed, inactive, incidental, insignificant, institution, intraFUSION, LCM, Mine, Mitigation, mortgage, MTS, nominal, noncancelable, noncurrent, occupational, Pennsylvania, pool, preservation, prospective, provisional, rebalance, recipient, refinancing, restitution, saving, script, semiannually, shift, shortfall, standing, step, stored, stranded, streamline, strength, Summit, Supplementary, tailored, tendered, uncollectible, wage, waiting, weakening

From filing 10-K 2021 FY